Skip to main content
Clinical Trials/NCT03434912
NCT03434912
Unknown
Not Applicable

Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy

MiCareo Taiwan Co., Ltd.1 site in 1 country80 target enrollmentMay 24, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
CTC and Tumor Related Rare Cell
Sponsor
MiCareo Taiwan Co., Ltd.
Enrollment
80
Locations
1
Primary Endpoint
Circulating tumor cell
Last Updated
7 years ago

Overview

Brief Summary

The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome. The secondary objective is to explore whether the changes of tumor related rare cells associates clinical outcome.

Registry
clinicaltrials.gov
Start Date
May 24, 2017
End Date
April 30, 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  • Over 20 years of age.
  • Cancer patients on immune checkpoint inhibitors.

Exclusion Criteria

  • Subjects who have other cancer history
  • Pregnant females
  • Subjects with active, known or suspected autoimmune disease.
  • Known history of human immunodeficiency virus (HIV)

Outcomes

Primary Outcomes

Circulating tumor cell

Time Frame: 1 years

Isolation and analysis of circulating tumor cells before and after immunotherapy

Secondary Outcomes

  • tumor related rare cell(1 years)

Study Sites (1)

Loading locations...

Similar Trials